Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
Total Valuation
Clarity Pharmaceuticals Ltd. has a market cap or net worth of AU$1.35B. The enterprise value is AU$1.12B.
Market CapAU$1.35B
Enterprise ValueAU$1.12B
Share Statistics
Clarity Pharmaceuticals Ltd. has 372,256,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding372,256,960
Owned by Insiders6.07%
Owned by Institutions―
Financial Efficiency
Clarity Pharmaceuticals Ltd.’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -76.10%.
Return on Equity (ROE)-0.71
Return on Assets (ROA)-0.64
Return on Invested Capital (ROIC)-76.10%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee189.26K
Profits Per Employee0.00
Employee Count50
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clarity Pharmaceuticals Ltd. is ―. Clarity Pharmaceuticals Ltd.’s PEG ratio is -0.37.
PE Ratio―
PS Ratio84.33
PB Ratio8.84
Price to Fair Value8.84
Price to FCF-14.52
Price to Operating Cash Flow-18.23
PEG Ratio-0.37
Income Statement
In the last 12 months, Clarity Pharmaceuticals Ltd. had revenue of 9.46M and earned -64.30M in profits. Earnings per share was -0.20.
Revenue9.46M
Gross Profit9.46M
Operating Income-69.09M
Pretax Income-63.88M
Net Income-64.30M
EBITDA-68.91M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -72.26M and capital expenditures -336.73K, giving a free cash flow of -72.59M billion.
Operating Cash Flow-72.26M
Free Cash Flow-72.59M
Free Cash Flow per Share-0.20
Dividends & Yields
Clarity Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.50
52-Week Price Change28.83%
50-Day Moving Average3.42
200-Day Moving Average3.54
Relative Strength Index (RSI)56.84
Average Volume (3m)3.27M
Important Dates
Clarity Pharmaceuticals Ltd. upcoming earnings date is Aug 26, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
Clarity Pharmaceuticals Ltd. as a current ratio of 9.69, with Debt / Equity ratio of 0.00%
Current Ratio9.69
Quick Ratio9.69
Debt to Market Cap0.00
Net Debt to EBITDA0.69
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Clarity Pharmaceuticals Ltd. has paid 416.51K in taxes.
Income Tax416.51K
Effective Tax Rate>-0.01
Enterprise Valuation
Clarity Pharmaceuticals Ltd. EV to EBITDA ratio is -10.89, with an EV/FCF ratio of -13.65.
EV to Sales79.29
EV to EBITDA-10.89
EV to Free Cash Flow-13.65
EV to Operating Cash Flow-13.70
Balance Sheet
Clarity Pharmaceuticals Ltd. has AU$226.25M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$226.25M billion.
Cash & Marketable SecuritiesAU$226.25M
Total DebtAU$0.00
Net CashAU$226.25M
Net Cash Per ShareAU$0.61
Tangible Book Value Per ShareAU$0.28
Margins
Gross margin is 96.85%, with operating margin of -730.16%, and net profit margin of -679.45%.
Gross Margin96.85%
Operating Margin-730.16%
Pretax Margin-675.05%
Net Profit Margin-679.45%
EBITDA Margin-728.21%
EBIT Margin-730.16%
Analyst Forecast
The average price target for Clarity Pharmaceuticals Ltd. is AU$7.70, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$7.70
Price Target Upside101.04% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-29.93%